Table 5.
Pairwise comparisons of relationships with all-cause and cardiovascular mortality for lipids, apolipoproteins, or their ratiosa.
| Hazard ratiosb (95% confidence intervals) | Hazard ratiosc (95% confidence intervals) | |||
|---|---|---|---|---|
| All-cause mortality | CVD mortality | All-cause mortality | CVD mortality | |
| Comparisons of single measures | ||||
| HDL-C | 0.91 (0.77–1.07) | 0.98 (0.82–1.18) | 1.05 (0.85–1.30) | 1.17 (0.88–1.42) |
| Apolipoprotein A-I | 0.92 (0.86–0.99) | 0.95 (0.88–1.03) | 0.91 (0.83–0.99) | 0.92 (0.83–1.02) |
| LDL-C | 1.02 (0.98–1.07) | 1.06 (1.01–1.12) | 1.11 (1.01–1.23) | 1.16 (1.04–1.29) |
| Total cholesterol | 1.00 (0.96–1.05) | 1.03 (0.98–1.08) | 0.92 (0.84–1.01) | 0.92 (0.83–1.01) |
| LDL-C | 1.02 (0.98–1.07) | 1.06 (1.01–1.12) | 1.08 (0.97–1.20) | 1.15 (1.02–1.28) |
| Non-HDL-C | 1.01 (0.97–1.06) | 1.04 (0.98–1.09) | 0.95 (0.86–1.05) | 0.92 (0.82–1.03) |
| Total cholesterol | 1.00 (0.96–1.05) | 1.03 (0.98–1.08) | 0.91 (0.77–1.07) | 0.97 (0.81–1.17) |
| Non-HDL-C | 1.01 (0.97–1.06) | 1.04 (0.98–1.09) | 1.12 (0.94–1.33) | 1.07 (0.88–1.29) |
| LDL-C | 1.02 (0.98–1.07) | 1.06 (1.01–1.12) | 1.03 (0.97–1.09) | 1.08 (0.99–1.17) |
| Apolipoprotein B | 1.01 (0.97–1.06) | 1.03 (0.98–1.07) | 0.99 (0.92–1.07) | 0.97 (0.86–1.10) |
| Apolipoprotein B | 1.01 (0.97–1.06) | 1.03 (0.98–1.07) | 1.02 (0.96–1.07) | 1.01 (0.95–1.08) |
| Total cholesterol | 1.00 (0.96–1.05) | 1.03 (0.98–1.08) | 1.00 (0.95–1.05) | 1.02 (0.97–1.09) |
| Apolipoprotein B | 1.01 (0.97–1.06) | 1.03 (0.98–1.07) | 1.01 (0.95–1.07) | 1.01 (0.94–1.08) |
| Non-HDL-C | 1.01 (0.97–1.06) | 1.04 (0.98–1.09) | 1.01 (0.95–1.06) | 1.03 (0.97–1.10) |
| Comparisons of ratio variables and single measures | ||||
| LDL/HDL ratio | 1.22 (1.06–1.40) | 1.27 (1.09–1.49) | 1.31 (1.08–1.58) | 1.37 (1.10–1.67) |
| LDL-C | 1.02 (0.98–1.07) | 1.06 (1.01–1.12) | 0.97 (0.91–1.03) | 0.98 (0.92–1.05) |
| LDL/HDL ratio | 1.22 (1.06–1.40) | 1.27 (1.09–1.49) | 1.28 (1.07–1.54) | 1.30 (1.07–1.58) |
| Apolipoprotein B | 1.01 (0.97–1.06) | 1.03 (0.98–1.07) | 0.96 (0.87–1.05) | 0.98 (0.89–1.08) |
| Apolipoprotein B/A-I ratio | 1.00 (0.93–1.08) | 1.00 (0.92–1.09) | 1.00 (0.91–1.09) | 0.99 (0.86–1.13) |
| LDL-C | 1.02 (0.98–1.07) | 1.06 (1.01–1.12) | 1.02 (0.98–1.07) | 1.07 (1.01–1.12) |
| Apolipoprotein B/A-I ratio | 1.00 (0.93–1.08) | 1.00 (0.92–1.09) | 1.00 (0.92–1.08) | 0.99 (0.89–1.11) |
| Apolipoprotein B | 1.01 (0.97–1.06) | 1.03 (0.98–1.07) | 1.01 (0.97–1.06) | 1.03 (0.98–1.07) |
| Comparison of ratio variables | ||||
| LDL/HDL ratio | 1.22 (1.06–1.40) | 1.27 (1.09–1.49) | 1.22 (1.06–1.42) | 1.29 (1.06–1.55) |
| Apolipoprotein B/A-I ratio | 1.00 (0.93–1.08) | 1.00 (0.92–1.09) | 0.98 (0.81–1.18) | 0.94 (0.54–1.66) |
aModel was adjusted for age, gender, education, marriage, leisure-time physical activity, smoking, alcohol drinking, type, severity, duration, treatment of CAD, history of diabetes, history of heart failure, BMI, systolic blood pressure, glomerular filtration rate, and use of antihypertensive drugs, antidiabetic drugs, antiplatelet drugs, and cholesterol-lowering drugs.
bEvery variable was introduced into the model singly.
cEvery pair of variables was simultaneously introduced into the model.